Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.

Histamine H3 receptor (H3R) antagonists have some antipsychotic properties although the clear molecular mechanism is still unknown. As actually the most effective and less side effective antipsychotics are drugs with multiple targets we have designed typical and atypical neuroleptics with an additional histamine H3 pharmacophore. The 4-(3-piperidinopropoxy)phenyl pharmacophore moiety has been linked to amitriptyline, maprotiline, chlorpromazine, chlorprothixene, fluphenazine, and clozapine. Amide, amine and ester elements have been used generally to maintain or slightly shift affinity at dopamine D(2)-like receptors (D2 and D3), to decrease affinity at histamine H(1) receptors, and to obtain H3R ligands with low nanomolar or subnanomolar affinity. Change of effects at D(1)-like receptors (D1) and (D5) were heterogeneous. With these newly profiled compounds different antipsychotic properties might be achieved.

[1]  J. Lehmann,et al.  Dopamine Receptor Ligands. Part VII [1]: Novel 3‐Substituted 5‐Phenyl‐1, 2, 3, 4, 5, 6‐hexahydro‐azepino‐[4, 5‐b]indoles as Ligands for the Dopamine Receptors , 2003, Archiv der Pharmazie.

[2]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[3]  Rob Leurs,et al.  Keynote review: histamine H3 receptor antagonists reach out for the clinic. , 2005, Drug discovery today.

[4]  J. Schwartz,et al.  General construction pattern of histamine H3-receptor antagonists: change of a paradigm. , 1998, Bioorganic & medicinal chemistry letters.

[5]  R. Leurs,et al.  Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells , 1996, British journal of pharmacology.

[6]  C. Ito.  The role of the central histaminergic system on schizophrenia. , 2004, Drug news & perspectives.

[7]  J. Schwartz,et al.  S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[8]  W. Geldenhuys,et al.  Multifunctional drugs with different CNS targets for neuropsychiatric disorders , 2006, Journal of neurochemistry.

[9]  Holger Stark,et al.  Histamine H3 receptor antagonists go to clinics. , 2008, Biological & pharmaceutical bulletin.

[10]  H. Haas,et al.  Histamine in the nervous system. , 2008, Physiological reviews.

[11]  T. Hase,et al.  Preparation of N-demethylated drug metabolites for analytical purposes using 1-chloroethyl chloroformate , 1997 .

[12]  C. Dvorak,et al.  A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. , 2003, Journal of medicinal chemistry.

[13]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[14]  Divya Vohora,et al.  The Third Histamine Receptor : Selective Ligands as Potential Therapeutic Agents in CNS Disorders , 2008 .

[15]  J. Witkin,et al.  Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.

[16]  C R Ganellin,et al.  Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.

[17]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[18]  B. Bondy,et al.  Pharmacogenetics of antipsychotics: useful for the clinician? , 2007, Current opinion in psychiatry.

[19]  Holger Stark,et al.  Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands. , 2007, Bioorganic & medicinal chemistry.

[20]  R. Leurs,et al.  The histamine H3 receptor: from gene cloning to H3 receptor drugs , 2005, Nature Reviews Drug Discovery.

[21]  C. Tamminga,et al.  The neuropharmacology of psychosis. , 2007, Schizophrenia bulletin.

[22]  R. Boyle,et al.  Photodynamic therapy: novel third‐generation photosensitizers one step closer? , 2008, British journal of pharmacology.

[23]  J. Kwon,et al.  A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. , 2008, The Journal of clinical psychiatry.

[24]  David A Lewis,et al.  Schizophrenia as a disorder of neurodevelopment. , 2002, Annual review of neuroscience.

[25]  J. Senet,et al.  A new reagent for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine , 1984 .

[26]  Michael Williams,et al.  Emerging opportunities for antipsychotic drug discovery in the postgenomic era. , 2008, Journal of medicinal chemistry.

[27]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.

[28]  J. Schwartz,et al.  Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. , 2007, Biochemical pharmacology.